Copyright
©The Author(s) 2016.
World J Gastroenterol. Feb 28, 2016; 22(8): 2415-2423
Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2415
Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2415
Figure 2 Fiblobrast growth factor receptor-targeted therapeutics.
Fibroblast growth factor receptors (FGFRs)-targeted tyrosine kinase inhibitors are small molecule ATP-competitive agents that bind to the ATP-binding site of the intracellular tyrosine kinase domain of FGFRs. Monoclonal antibody targets the extracellular domain of the FGFR and blocks ligand binding. RNA interference suppresses the expression of various genes. RNAi: RNA interference.
- Citation: Yashiro M, Matsuoka T. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer. World J Gastroenterol 2016; 22(8): 2415-2423
- URL: https://www.wjgnet.com/1007-9327/full/v22/i8/2415.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i8.2415